SPARC Sells Priority Review Voucher for US $195 Million

Sun Pharma Advanced Research Company Ltd (SPARC) has entered into an agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for US $195 million. The PRV was granted by the U.S. Food and Drug Administration (FDA) for the approval of Sezaby®, a treatment for neonatal seizures. The sale will enable SPARC to accelerate the development of its pipeline assets and strengthen its external innovation strategy. The transaction is subject to customary closing conditions.